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Abstract
Objective—A Phase I double blinded clinical trial was conducted to evaluate the effects of a high
oral dose of soy isoflavones administered daily for 84 days to healthy, postmenopausal women.
Principal outcome measures included DNA damage, apoptosis and changes indicative of estrogenic
stimulation.
Design—After eligibility and equol-producer status were determined, stratified randomization was
used to assign subjects to the isoflavone (active) or placebo group. Of the 30 subjects who completed
the study, 18 were in the active group. DNA damage was assessed via COMET and apurinic/
apyrimidinic site assays in lymphocytes. Apoptosis was evaluated via TUNEL and activated
Caspase-3 assays in lymphocytes. Estrogenic/antiestrogenic effects were assessed using a self-report
questionnaire and by assaying for estrogen, follicle-stimulating hormone, luteinizing hormone, and
sex hormone binding globulin in blood.
Results—In treated postmenopausal women there was no indication that high doses of soy
isoflavones caused DNA strand breakage, increased AP sites, or increased apoptosis in peripheral
lymphocytes. There were no significant changes in mean values for estrogenic effects or other
laboratory measurements. Very few adverse events occurred and the only drug-related adverse events
were mild or grade 1 in severity.
Conclusions—Unconjugated soy isoflavones appear to be safe and well tolerated in healthy
postmenopausal women at doses of 900 mg per day.
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INTRODUCTION
Many women supplement their diets with soy isoflavones because case-control studies
conducted in China [1], and in Asian-Americans [2,3], as well as a prospective cohort study
from Japan [4] showed an inverse relationship between soy intake and breast cancer risk. The
chemopreventive effects of soybeans and soy-containing foods may be related to their
isoflavone content [5,6,7,8,9]. Daily intakes of 39–47 mg/day isoflavones have been reported
in Japanese populations [10,11]. In the United States, dietary consumption of soy isoflavones
in the general population is much less than this amount (< 5mg/day) and diet supplements are
being used to increase daily intake. These isoflavones exert multiple effects including estrogen
receptor activation [12,13] as well as antiestrogenic actions [14], antioxidant activity [14],
inhibition of growth factor receptor signaling via tyrosine kinases [15,16,17,18], induction of
apoptosis [19,20,21,22], induction of cell differentiation [23], and inhibition of angiogenesis
[24].
Some investigators reported that soy isoflavones, particularly genistein, caused gene damage
[25]. Genistein induced mammalian topoisomerase II dependent DNA cleavage in purified
broken cell preparations [26] and at high doses induced the production of large numbers of
micronuclei (a measure of chromosomal damage) in mouse splenocytes in culture [27].
However, our earlier study in men treated with high dose soy isoflavones did not confirm this
[28]; there was no increase in double stranded breaks in DNA. There is also significant concern
that soy isoflavones have estrogenic actions that might increase proliferation in estrogen
receptor positive breast cancers [29]. Soy isoflavones bind to both estrogen receptors (ER) α
and β and are 1/1000 as potent as estrogen in activating ERα and 1/3 as potent as estrogen for
ERβ [30]. At this time, there is considerable controversy as to whether isoflavones are net
estrogen agonists [13,29,31] or whether they act via antiestrogenic effects [32]. One possible
explanation may have to do with variations among women in the capacity to form the isoflavone
metabolite, equol [33,34]. Equol binds to both ERα and ERβ and remains in circulation longer
than do genistein or daidzein [33,34]. The capacity to form equol depends on colonization of
the intestine with certain bacteria, and occurs in approximately 20–35% of the Western adult
population and 50–55% of the population living in Asian countries [33]. The objective of this
study was to determine whether or not healthy postmenopausal women developed estrogenic
effects, genotoxicity or increased apoptosis when treated orally with a high dose isoflavone
mixture (70% unconjugated isoflavones containing genistein, daidzein and glycitein) for 84
days. In addition, we determined whether women, who produced the daidzein metabolite,
equol, differed in these outcome markers from women who did not.
METHODS
Subjects
Healthy, non-obese postmenopausal women were recruited from the Research Triangle area
of North Carolina by advertisements placed in local newspapers, mass informational emails,
and flyers placed in strategic locations such as grocery stores, and churches. Postmenopausal
status was defined as having last spontaneous menstrual bleeding > 12 months ago and follicle
stimulating hormone (FSH) > 30 mIU/mL (later amended to 27 mIU/mL as the laboratory
method used for the analysis changed). Non-obese was defined as a body mass index (BMI)
< 35 kg/m2. Women taking hormone/estrogen therapy or selective estrogen receptor
modulators (SERMS) within three months of enrollment or at high risk of breast cancer (five-
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year risk of 1.9% or higher) as assessed by NCI’s Breast Cancer Risk Assessment Tool
(http://bcra.nci.nih.gov) were excluded. Use of oral antibiotics within the three months prior
to enrollment, supplements containing isoflavones within one month prior to enrollment,
current tobacco use, or routine alcohol ingestion > 2 drinks/day were also reasons for exclusion.
Before acceptance into this study, the volunteer’s health was verified by medical history,
physical examination by a licensed medical doctor, screening laboratory tests, chest x-ray and
electrocardiogram. In addition, the subject was required to furnish copies of negative
mammogram and Pap smear reports dated within the last year.
Seventy-two women met eligibility criteria based on an initial telephone screen and were
scheduled for a two-part screening appointment. Thirty-eight subjects met initial eligibility
after screening and 36 women were enrolled. One subject was terminated from the study due
to FSH levels that were too low. Another two subjects completed the study, but their
information was dropped because it was later determined that their pre-study mammograms
were not normal. Three other subjects decided not to complete the study. One subject moved
to another state, one stated that the study supplement made her irritable and another claimed
personal reasons for not completing the study. The remaining 30 subjects successfully
completed the study. Demographic information on these subjects is presented in Table 1.
The subjects provided written, informed consent, and the study was conducted in accordance
with the guidelines of the Institutional Review Board of the School of Medicine at the
University of North Carolina (UNC) at Chapel Hill. We operated under an Investigational New
Drug (IND) application (no. 54137) for the isoflavone preparation, which was obtained from
the Food and Drug Administration by the National Cancer Institute (NCI) for use in cancer
prevention trials. Westat (Rockville, Maryland), the monitoring agency designated by NCI,
conducted a complete evaluation of study procedures and study event documentation.
Equol status
After eligibility was determined, all subjects ingested 473.2 mL of soy milk containing 50 mg
of daidzein [33] to determine if they were producers of the daidzein metabolite equol. After
18 hours, blood was collected and serum equol was determined by Dr. Kenneth Setchell at
Cincinnati Children’s Hospital Medical Center using high-pressure liquid chromatography
mass spectrophotometry [33,34]. Equol producers were defined as individuals with plasma
equol concentrations > 20μg/L; non-equol producers as those with equol concentrations <
10μg/L. Individuals with intermediate equol concentrations (≥ 10 μg/L to ≤ 20 μg/L) were to
be excluded from the study; however, reanalysis of plasma samples revealed that one included
subject was an intermediate producer.
Isoflavones formulation and dosage
Protein Technologies International (PTI; St. Louis, MO), via the National Cancer Institute,
provided hard gelatin capsules that contained ≥ 70% active substance as total unconjugated
isoflavones (PTI G-2535 Unconjugated Isoflavones–70). Isoflavones were produced under
Good Manufacturing Practices guidelines. University Pharmaceuticals of Maryland
Incorporated (Baltimore, MD) formulated each capsule to contain 150 mg genistein activity.
The composition of PTI G-2535 capsules (Lot # UPM 9809-021) used in this clinical study
was as follows: genistein 139.5 mg per capsule, daidzein 74 mg per capsule and glycitein 11
mg per capsule. Two laboratories (Ralston Analytical Laboratories, St. Louis, MO; Sigma
Chemical Laboratories, St. Louis, MO) independently analyzed isoflavone composition and
concentrations. The preparation was stable at 40°C and 70°C for at least 6 months, and at 25°
C for 3 years (assays performed at University Pharmaceuticals of Maryland, Inc.). The placebo
capsules were identical in size and color, and contained excipients from the active formulation.
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The study was conducted at the UNC General Clinical Research Center (GCRC). On day 1
(pre-study drug), blood was drawn from the antecubital vein for pre-study determinations and
stratified randomization (based on equol producer vs. non-producer status) was then used to
assign the eligible subjects to Active or Placebo groups.
The Active group (n= 18) received 4 capsules of dietary supplement PTI G-2535 (containing
approximately 600 mg genistein/day – about ten times the dose conventionally used in diet
supplements - and half this much daidzein) divided into two equal daily doses. The Placebo
group (n= 12) received the same number of placebo capsules. Subjects self-administered the
capsules with food both in the morning and in the evening for 84 days. In order to effectively
monitor genistein concentrations, subjects were instructed not to consume diets containing >
20 mg genistein/day while enrolled in the study. Most subjects chose to abstain from soy
altogether during their study participation. Follow-up visits were conducted on days 2, 7, 14,
28, 56, 84 and 112.
Monitoring of compliance and safety
Compliance was determined using capsule counts and total plasma genistein concentrations
(blood sample drawn before the next dose in the morning on days 2, 7, 14, 28, 56 and 84).
Plasma was analyzed for total genistein using high-pressure liquid chromatography as
previously described [35] except that we used an electrochemical detector (ESA Inc,
Chelmsford, MA). We used trough genistein concentrations to detect individuals who
accumulated genistein on the treatment, and reduced the administered dose by 50% if the trough
concentration exceeded 10,000 ng/mL (this level is based on the highest trough level (7300
ng/mL) seen in a previous study [28], with a 33% margin added). All subjects were followed
until 112 days after initiation of the study; 28 days after cessation of treatment.
Treatment toxicity was monitored with a panel of blood tests collected on days 1, 14, 28, 84,
and 112, consisting of a complete blood count (CBC), blood urea nitrogen (BUN)/creatinine
ratio, alkaline phosphatase (AP), alanine aminotransferase (ALT), aspartate aminotransferase
(AST), gamma-glutamyl transferase (GGT), amylase, lipase, and triglycerides. An additional
toxicity panel consisting of electrolytes, calcium, magnesium, phosphorus, lactate
dehydrogenase, albumin, uric acid, total bilirubin, fibrinogen, prothrombin time (PT), partial
prothrombin time (PTT), thyroxine (T4), thyroid-stimulating hormone (TSH), triiodothyronine
(T3) uptake, and free thyroxine index (FTI) was measured on days 1, 28, 84, and 112. Finally,
blood pressure measurements were taken on days 1, 2, 7, 14, 28, 56, 84 and 112.
Per the regulations set forth by the UNC Institutional Review Board, all adverse events were
classified by the study physician as mild, moderate, or serious, and were graded according to
the National Cancer Institute’s Common Toxicity Criteria. Moreover, the study physician
deemed these events 1) not or unlikely related to the study, 2) unknown, or 3) probably or
definitely related to the study using her best clinical judgment. Specifically, if the adverse event
was anticipated based on our previous results, or in the published literature, and was temporally
related to isoflavone treatment, then it was deemed as probably study related. If the relation of
the event to isoflavone treatment was not conclusively related, but could not be ruled out, then
the attribution of the event to the isoflavone treatment was deemed as unknown. Events which
were clearly unrelated to isoflavone treatment (for example events of known etiologies, or
events which temporally preceded the first isoflavone dose) were deemed as unlikely study
related. All subjects in whom adverse events occurred were followed according to Good
Clinical Practice guidelines until resolution of the events.
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Assessment of estrogenic/antiestrogenic effects
Estrogenic/antiestrogenic effects of isoflavones were measured using a self-report
questionnaire covering menopausal side effects (including hot flashes, chest pain, shortness of
breath, leg cramps or swelling, breast tenderness, breast enlargement, changes in sex drive,
nausea or vomiting) and by measuring serum concentrations of estrogen, FSH, luteinizing
hormone (LH), and sex hormone binding globulin (SHBG) on days 1, 84, and 112. Attempts
were made to obtain endometrial biopsy samples from all subjects pre- and post-dose, but we
were unable to collect sufficient material to assess the estrogen-responsiveness of this tissue.
Assessment of genotoxicity and apoptosis
The potential of genistein to induce DNA damage was assessed via COMET assay in
lymphocytes collected on days 1 and 84. This result was complemented by apurinic/
apyrimidinic (AP) sites assay in lymphocytes on the same days. Changes in apoptosis were
evaluated via terminal deoxynucleotidyl transferase-mediated dUTP nick end labeling
(TUNEL) and Caspase-3 activation assays conducted on lymphocytes collected on days 1 and
84.
Peripheral lymphocytes were isolated from blood using Ficoll-Hypaque gradient in evacuated
tubes with sodium citrate (Vacutainer CPT; Becton Dickinson, Franklin Lakes, NJ) according
to manufacturer’s instructions [36,37]. Single cell gel electrophoresis (COMET) was
performed as described previously [38,39,40]; this assay detects changes in DNA migration
caused by strand breaks, alkaline labile sites or transient repair sites. Lymphocytes were
sandwiched between 0.5% regular agarose solution (Fisher, Fair Lawn, NJ) and 0.5% Low
Melting Point Agarose (37°C; Fisher). The resulting slides were placed into cold, freshly made
lysis solution (10 mmol/L Tris base, pH 10, 2.5 mol/L NaCl, 100 mmol/L EDTA, 1% Sodium
Sarcosinate, 10% DMSO, and 1% Triton X-100). Slides were placed in the refrigerator for a
minimum of 1 h, and then pretreated for 20 min in electrophoresis buffer (300 mmol/L NaOH,
1 mmol/L EDTA, pH 13) for 20 min. Electrophoresis was performed at 25 volts and 300 mA
for 20 min. After electrophoresis, slides were incubated three times for 5 min in neutralization
buffer (0.4 mol/L Tris-HCl, pH 7.5), washed with methanol and stained with ethidium bromide
(20 μg/mL; Sigma-Aldrich). For visualization of DNA damage, observations were made at
400x magnification using an Olympus AX70 fluorescent microscope (Olympus Corporation,
Lake Success, NY). Typically 100 cells were analyzed per sample time point using cell image
analysis software (Scion Corporation, Frederick, MD), and the COMET tail moment was
calculated using a program in the NIH Image Analysis Macro language (National Technology
Information Service, Springfield, VA).
The number of AP sites in genomic DNA from lymphocytes was quantified using a slot-blot
method in which an aldehyde reactive probe was reacted with the aldehydic group of ring-
opened AP sites, as previously published [41]. The formation of AP sites can lead to the
induction of base substitution mutations or inhibition of DNA replication [42].
We measured DNA fragmentation in lymphocytes by TUNEL using ApopTag in Situ
Apoptosis Detection Kit (Chemicon International, Tamecula, CA). Lymphocytes were fixed
in 2% paraformaldehyde, and suspended on a silanized microscope slide by cytospin.
Following fixation the slides were stained with diaminobenzidine-peroxidase, and the nuclei
counterstained with 0.5% methyl green. The slides were mounted, and the percent of TUNEL
positive cells counted by light microscopy. At least 200 total cells were counted for each data
point and the amount was expressed in percentage. We also assessed apoptosis using the Signal
Stain Cleaved Caspase-3 (Asp175) IHC Detection Kit (Cell Signaling Technology, Danvers,
MA). Briefly, this method detects endogenous levels of the large fragment (17/19kDa) of
activated caspase-3 resulting from cleavage adjacent to Asp175. Lymphocytes were fixed in
Pop et al. Page 5













2% paraformaldehyde and suspended on a silanized microscope slide by cytospin. Slides were
incubated with prediluted cleaved Caspase-3 (Asp175) antibody which is bound by biotinylated
secondary antibody. Avidin DH and horseradish peroxidase were complexed by mixing
defined amounts prior to use, and the mixture subsequently was used to bind the secondary
antibody. The macromolecular complex was localized by incubation with NovaRed enzyme
substrate and the positive cells counted by light microscopy (at least 200 cells for each data
point).
Statistical analysis
To examine the effect of treatment group (active or placebo) and time on trough plasma
genistein concentrations, a repeated measures regression model was fit and various correlation
structures were examined to take into account the fact the measures over time on the same
person will be correlated. An unstructured correlation ultimately proved best. Treatment group
and time as well as a treatment group by time interaction term were included in the model.
Descriptive and inferential statistical analyses were performed in order to look for trends that
would point to differences in estrogenic effects, clinical laboratory tests, blood pressure,
genotoxicity and apoptosis. Non-stratified (Active versus Placebo) and stratified (active equol-
producers versus active non-equol producers) data were studied. Descriptive statistics (n, mean,
standard error) were calculated for the measurements collected at day 1 and day 84, for the
control and treatment groups and for the treated equol producer and non-equol producer groups.
A permutation test was used to detect any differences in the mean change from day 1 to day
84 in the continuous response variables between groups (treated versus placebo and treated
producers versus treated non-producers) and for the compared mean between groups at day 1
and day 84. A Fisher’s exact test was used to detect any differences in the proportion of subjects
that experienced side effects between the two groups. All analyses requiring a permutation test
were performed using StatXact 4 (1989–1999, CYTEL Software Corporation, Cambridge,
MA). All analyses using a Fisher’s exact test were performed using SAS package Version 9.1
(SAS, Cary, NC). Based on COMET assay data (means, standard deviations) observed in our
last study of isoflavone supplementation in men with prostate cancer (28), the current study
had 80% power to detect a mean difference of 0.43 in COMET tail moment between the
supplemented and control groups. A two-sided significance level of 0.05 was used for all
statistical tests.
RESULTS
Demographic information on the subjects enrolled in the study is presented in Table 1. The
mean age of subjects in the active group was 56.8 y and in the placebo group was 53.5 y. The
mean Body Mass Index (BMI) of subjects in the active group was 26.2 and in the placebo group
was 25.2. The demographic profile for all of the subjects collectively who completed the study
was 86.7% Caucasian, 10.0% African-American, and 3.3% (1 subject) Asian-American.
Equol producers versus non-equol producers
Among the 30 volunteers completing the study, there were six equol producers (20%; range:
21.8 to 46.6 ng/mL) and 23 non-producers (80%; range: 0 to 8.5 ng/mL; See Table 1). Of these,
4 were assigned to the Active group and 2 were assigned to the Placebo group. One subject
was an intermediate producer (12.9 ng/mL) and was assigned to the active group. As the number
of equol producers was so small, results for producers and non-producers were pooled.
However a cautious comparison of results seen in producers relative to non-producers in the
Active group is presented at the end of the results section.
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Two subjects in the Active treatment group had trough genistein concentrations that measured
above the 10,000 ng/mL cut-off and thus had their daily dose halved as a result. A third subject
in the active treatment group had her daily dose halved on day 2 due to her low body weight
and because her trough genistein concentration measured close to 10,000 ng/mL on day 2. All
subjects in the Active group (n = 18) had measurable trough genistein concentrations at every
follow-up study visit; the mean trough level during the treatment phase (through Day 84) being
3103 ng/mL. The mean trough genistein concentration among the 12 subjects in the Placebo
group was 11 ng/mL. Genistein trough levels (means and standard errors) for each follow-up
study visit are given in Table 2.
Adverse Events and Safety Data
A summary of all adverse events, judged to be probably or possibly related to soy isoflavone
administration, is presented in Table 3. (Note: subjects were monitored during the entire study
for safety reasons and data was collected for each study day, but the statistical analysis was
made only for days 1 (baseline) and 84 (end of treatment) to determine the significant changes
that may have occurred during the study).
Analysis of the laboratory clinical measurements showed no significant change in the mean
difference at day 84 from day 1, when comparing Placebo and Active groups. One subject, on
placebo, experienced a Grade 1 asymptomatic elevation in TSH (4.74 μU/ml, reference range
0.46–4.68 μU/mL) on Day 28 that returned to normal by the next visit. This same subject had
a decreased T4 (5. 3 μg/dL; reference range 5.5–11.0 μg/dL) measurement on Day 84. Further
investigations made by her primary care physician showed normal thyroid indices. Isolated
decreases in T4 (not graded) occurred in four other subjects, one on active treatment (5.0 μg/
dL; reference range 5.5–11.0 μg/dL) and three on placebo (5.1 μg/dL, 5.1 μg/dL, and 5. 2 μg/
dL; reference range 5.5–11.0 μg/dL). By the end of the study the T4 values were normal in all
subjects. Other thyroid indices for these 4 subjects were within normal limits at all measurement
points. At no time did any of the five subjects who experienced out-of-reference-range thyroid
indices complain of any of the symptoms of hypothyroidism. Measurements made at all other
study visits were within the normal range. One treated subject experienced one transient Grade
1 elevation of AST (44 U/L; reference range 14–38 U/L) on study day 28 which was deemed
possibly related to study drug. This same subject had one episode of elevated triglycerides (340
mg/dL; upper limit of normal = 300 mg/dL) on study day 14 which met Grade 1 criteria and
was judged possibly related to study drug. One subject in the Placebo group experienced one
episode of Grade 1 elevation in amylase (132 U/L; reference range 30–110 U/L) on Day 14,
which was deemed unlikely related to study drug.
Two subjects in the Active group experienced intermittent episodes of increased blood pressure
(148/70 mmHg; 158/98 mmHg) that were judged to be possibly related to taking study drug
(Table 3). When statistical analysis was performed, no significant changes in mean systolic or
diastolic blood pressure were noted (Table 4).
Estrogenic/antiestrogenic effects
There were no clinically significant changes in estrogenic/antiestrogenic laboratory
measurements (estrogen, FSH, LH, SHBG) (Table 4) between the groups. One subject on
placebo experienced decreased FSH (11.0 mIU/L; reference range 21.5–131 mIU/L) and LH
(6.2 mIU/L; reference range 13.1–86.5 mIU/L) levels on day 84. These levels were within the
normal range when measured on day 112. Another subject on placebo had increased estrogen
on day 1 (25 pg/ml; reference range <20 pg/mL), which returned to normal during the study
and increased again on day 112 (60 pg/ml; reference range <20 pg/mL). Her estrogen value
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was normal when rechecked on day 133. All three lab abnormalities were considered adverse
events that were possibly related to study drug (Table 3).
Information on estrogenic effects of soy isoflavones was also assayed by a self report
instrument which asked about hot flashes, breast changes and other menopausal symptoms
(Table 3). Throughout the course of the study eight of eighteen (44%) subjects in the Active
group reported estrogenic or anti-estrogenic effects, three-fourths of these being increases in
severity or frequency of hot flashes. In the Placebo group over the whole course of the study,
four of the twelve (33%) subjects reported estrogenic or anti-estrogenic effects, three-fourths
of these being increases in frequency of hot flashes. In order to assess effects on hot flashes
after prolonged soy treatment, a statistical analysis of all subjects experiencing hot flashes
between study days 56 and 84 was performed. During this period, fifty percent (6 of 12) of the
subjects on placebo reported increased hot flashes frequency, while 17% (3 of 18) of the
subjects on isoflavones did so (proportions not significantly different). One subject on placebo
reported increased breast tenderness on day 84.
Genotoxicity and apoptosis
The means for COMET, TUNEL and Caspase-3 assays were similar for the active and placebo
groups at baseline (day 1) and day 84. The mean for AP-site number at day 84 was higher in
the Placebo group (p<0.05), however, there were no significant differences between the
Placebo and Active groups in mean change in AP site number from day 1 to day 84 (Table 4).
Equol producer status –possible effects
A secondary aim of this study was to determine whether women who are equol-producers have
different responses to isoflavones than women who are not equol-producers. Twenty percent
(six subjects) of the subjects enrolled in the study were equol producers. This percent is
comparable to what has been reported in the literature (33). The number of producers may have
been slightly smaller in our study due to the small sample size and random variation. Despite
these small numbers, we statistically analyzed the producers versus non-producers from the
Active group in order to generate hypotheses about the impact of equol production status on
response to isoflavone administration. Analysis of the laboratory clinical measurements
showed no statistically significant difference in mean values at day 1 and day 84. Means
between the groups were comparable, except that neutrophil count at day 1 was significantly
higher for treated non-producers. There were no differences between groups in COMET,
TUNEL or AP-site assay. However, activated Caspase-3 was higher in treated producers on
day 1 and between days 1 and 84, equol-producers in the Active group decreased Caspase-3
activation, while non-producers increased activation, although none of these results were
statistically significant. There was a significant difference between the non-producers and
producers of equol in the Active group in the percentage of subjects who experienced hot
flashes as reported on day 84. No subjects reported hot flashes in the non-producers group on
isoflavones, while 50% reported hot flashes in the producer group.
DISCUSSION
In a previous study in men with prostate cancer, we reported little toxicity or estrogenicity after
84 days of treatment with high dose isoflavones [28]. However, as all of these men had taken
or were on a stable course of hormone therapy as part of their cancer treatment, it was difficult
to determine the relationship of any observed symptoms to isoflavone administration. In the
same study, the potential genotoxicity of isoflavone administration also was examined. Overall,
no changes in average COMET occurred over the course of the treatment. However in 3
individuals we observed increases in COMET, and in one of these individuals we observed an
increased micronucleus frequency. As this previous study was conducted in subjects who had
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cancer and who were potentially exposed to genotoxic drugs and treatments, it was difficult to
definitively determine the relationship of isoflavones to the observed genotoxic effects. For
this reason, in the present study we administered high dose isoflavones to healthy individuals
at a daily dose that greatly exceeded (by approximately 10-fold) doses likely to be self-
administered by those using dietary supplements.
As discussed earlier, several studies conducted in cell culture showed DNA damage and
micronucleus formation after exposure to genistein [25,26,43,44,45,46]. In this study we found
no evidence for genotoxicity in the lymphocytes of the healthy subjects exposed to high doses
of isoflavones. This suggests that short term supplementation (84 days) with high doses of soy
isoflavones is safe in postmenopausal women.
In previous studies it was shown that genistein induced apoptosis in cells by inhibiting tyrosine
kinase growth signaling [22,47,48]. Also, topoisomerase II, an enzyme involved in the
relaxation and uncoiling of DNA (decatenation), is inhibited by genistein [49]. This process
involves double strand breaks followed by religation [49,50]. We observed no significant
changes in apoptosis as assessed by TUNEL for any of the groups in our study. Caspase-3 was
not significantly different between placebo and treated groups. The fact that between days 1
and 84, equol-producers in the Active group decreased Caspase-3 activation, while non-
producers increased activation (not statistically significant) however suggests that equol itself
may inhibit apoptosis, or, alternatively, that the diversion of daidzein to form equol may lower
the concentration of an active constituent or metabolite derived from isoflavones that induces
apoptosis.
There was a trend toward lower incidence of hot flashes after three months on the soy
isoflavones but overall we cannot conclude that soy isoflavones will reduce symptoms
associated with menopause if used in postmenopausal women as these self-reported symptoms
are prone to reporter bias and placebo effects. The significant difference between the non-
producers and producers of equol in the Active group in the percentage of subjects who
experienced hot flashes as reported on day 84 suggests that equol production status may
increase the anti-estrogenic potential of soy isoflavones.
There were no clinically significant changes in hormone or hormone-related laboratory values
that suggested estrogenic or antiestrogenic activity of isoflavones in postmenopausal women.
This is an important observation, as concerns about potential estrogenic activity of isoflavones
has limited their use as a dietary supplement in women for fear that latent breast cancer cells
might be stimulated to grow [51]. However, the lack of changes in hormone levels can only
be taken as correlative and not as absolute evidence that soy isoflavones did not exhibit
estrogenic activity in this sample of postmenopausal women. Unfortunately, the estrogenic
potential of the soy isoflavones was not directly assessed in an estrogen-dependent tissue such
as vagina or uterus. Attempts were made to collect endometrial biopsy samples, but insufficient
tissue was available to look at pathological or biochemical changes. Thus any assessment of
soy isoflavone estrogenicity must be interpreted with caution.
It is well known that menopause is associated with a dramatic rise in prevalence of hypertension
in women and previous clinical and animal investigations have suggested that estrogen has a
protective role against hypertension. However some clinical trials have found contradictory
results [52]. Conflicting evidence on the effects of soy isoflavones on blood pressure also has
been reported [53]; thus, we asked if a very high dose of isoflavones would make a difference
and establish a directional effect of soy on blood pressure. The results of our analysis suggest
that 84 days of treatment with soy isoflavones did not result in appreciable changes in blood
pressure.
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In summary, these results suggest that unconjugated soy isoflavones are safe and well tolerated
in healthy postmenopausal women at doses of 900mg per day. Very few adverse events
occurred and the only drug-related adverse events were mild in severity. Although there has
been considerable debate on the estrogenic potential of isoflavones, our study showed only
very minimal effects. However, as narrow inclusion-exclusion criteria were chosen due to
potential safety reasons related to treating post-menopausal women with very high doses of
soy isoflavones these results may not hold for all post-menopausal women. Equol could be an
important modulator of soy isoflavones and larger studies on the effects of isoflavone
supplementation in humans are warranted.
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TABLE 1
Subject demographics and equol production status
Group Mean Age (years) Mean BMI (kg/m2) Race Equol status













BMI= body mass index. Race was determined by subject report. Equol producer status was determined using a soy milk (containing 50 mg of daidzein)
feeding challenge. After 18 hours, blood was collected and serum equol was determined. Equol producers were defined as individuals with plasma equol
concentrations > 20μg/L; non-equol producers as those with equol concentrations < 10μg/L. Individuals with equol concentrations ≥ 10 μg/L to ≤ 20 μg/
L were defined as intermediate producers.
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Table 3
Adverse events reported during isoflavone administration
Event Type Number in Active Subjects Number in Placebo Subjects
Grade 1 adverse events possibly related to isoflavones
Increased blood pressure 2 0
Increased AST 1 0
Increased triglycerides 1 0
Increased estrogen 0 1
Decreased FSH/LH 0 1
Increased TSH 0 1
Decreased T4 1 4
Flatulence 0 1
Grade 1 adverse events probably related to isoflavones
Nausea 1 0
Swelling in legs (mild) 0 1
Breast tenderness 0 1
Self-reported estrogenic/anti-estrogenic effects possibly related to isoflavones
Hot flashes (Increased intensity or frequency) 6 3
Hot flashes (Decreased intensity) 1 1
Increased breast size or tenderness 2 0
Subjects were asked to report any side effects noticed during their study participation.
Abbreviations: AST- aspartate aminotransferase, FSH-follicle stimulating hormone, LH-luteinizing hormone, TSH – thyroid-stimulating hormone, T4-
tyroxine.
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